Durable Benefit From PARP Inhibitors in Patients With Metastatic Prostate Cancer in Routine Practice According to Molecular Subgroups
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing
ESMO Open 2024 Sep 09;9(9)103684, D Triner, RP Graf, RW Madison, O Gjoerup, H Tukachinsky, JS Ross, JCF Quintanilha, G Li, HH Cheng, CC Pritchard, AJ Zurita, Q Qin, T Zhang, N Agarwal, ZR Reichert, J Mateo, M Cieslik, TM MorganFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.